Company intelligence / Profile preview
Agni Bio
San Francisco, CA, USAagnibio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Agni Bio is a preclinical-stage biotechnology company focused on developing next-generation mitochondrial uncouplers for the treatment of metabolic disorders. The company's platform targets the safe modulation of mitochondrial respiration to increase energy expenditure, offering a potential therapeutic approach for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). By leveraging novel small molecule chemistry, Agni Bio aims to overcome the toxicity challenges historically associated with mitochondrial uncoupling agents like DNP. The company was part of the Y Combinator Winter 2021 cohort and is headquartered in San Francisco.
- Therapeutic areas
- EndocrinologyMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Agni Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Agni Bio.